Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.06.022 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Panu Wetwittayakhlang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada; Gastroenterology and Hepatology Unit, Div…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: We aimed to evaluate clinical efficacy, biomarker activity, therapeutic drug monitoring (TDM), adverse events (AEs), and nocebo effect in inflammatory bowel disease (IBD) patients who underwent non-medical biosimilar switching. METHODS: A prospective observational study of consecutive IBD patients who underwent biosimilar switch. Disease activity, biomarkers, TDM, and AEs, including the nocebo effect were captured 8 weeks before switch, at the time of switch (baseline),12 and 24 weeks after the switch. RESULTS: 210 patients were included [81.4% had Crohn's disease (CD), the median age at inclusion: 42 years (IQR 29-61)]. There was no significant difference in the rates of clinical remission at week 8 before switch, baseline, week12, and 24 after switch: 89.0%,93.4%,86.3%,and 90.8%,p = 0.129. The biomarker remission rates were not significantly different; CRP:81.3%,74.7%,81.2%,73.0%,p = 0.343; fecal calprotectin: 78.3%,74.5%,71.7%,76.3%,p = 0.829. The rates of maintaining therapeutic levels (84.7%,83.9%,83.0%,85.3%,p = 0.597) and prevalence of positive anti-drug antibodies remained unchanged. Drug persistence at 12 week of switch was 97.1%, regardless of disease phenotype and originator. The nocebo effect was observed in 13.3%. The discontinuation rate was 4.8%. CONCLUSION: Despite a significant number of early nocebo complaints within the first 6 months after the biosimilar switch, no significant changes were found in clinical efficacy, biomarkers, therapeutic drug level, or anti-drug antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada; Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla Uni…
- Division of Internal Medicine McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada.
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada.
- Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada; Department of Internal Medicine and Oncology, Semmelweis University, Budapest H-1085, Hungary. Electronic addre…
Zitieren
APA
Wetwittayakhlang, P., Karkout, K., Wongcha-Um, A., Tselekouni, P., Al-Jabri, R., Afif, W., Wild, G., Bitton, A., Bessissow, T., & Lakatos, P. L. (2024). Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.06.022
Vancouver
Wetwittayakhlang P, Karkout K, Wongcha-Um A, Tselekouni P, Al-Jabri R, Afif W, et al. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.06.022
BibTeX
@article{Wetwittayakhlang2024,
author = {Wetwittayakhlang, Panu and Karkout, Khaled and Wongcha-Um, Arti and Tselekouni, Paraskevi and Al-Jabri, Reem and Afif, Waqqas and Wild, Gary and Bitton, Alain and Bessissow, Talat and Lakatos, Peter L},
title = {Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.06.022}
}
EUVIMED